Anti-PD-L1 Antibody

1/1
Price:
Size:
Number:

Anti-PD-L1 Antibody (Rabbit Monoclonal 抗体) の製品情報

製品名
Anti-PD-L1 Antibody
検証済のアプリケーション
ELISA,IHC-P
交差反応
Reacts with: Human
特異性
Human PD-L1
No cross-reactivity in ELISA with
Human B7-1
Human B7-2
Mouse B7-H1
Non-blocking
This B7-H1/PD-L1 antibody can not block the binding of recombinant PD1 (10377-H03H) to its recombinant ligand B7-H1/PD-L1 (10084-H02H).
免疫原
Recombinant Human PD-L1 / B7-H1 / CD274 protein (Catalog#10084-H08H)
調製
This antibody was obtained from a rabbit immunized with purified, recombinant Human PD-L1 / B7-H1 / CD274 (rh PD-L1 / B7-H1 / CD274; Catalog#10084-H08H; NP_054862.1; Met 1-Thr 239).
ソース
Monoclonal Rabbit IgG Clone #015
精製
Protein A
緩衝液
0.2 μm filtered solution in PBS
標識物
Unconjugated
状態
Liquid
配送方法
This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
保存条件
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles.

Anti-PD-L1 Antibody (Rabbit Monoclonal 抗体) 検証済のアプリケーション

アプリケーション 推奨希釈率/用量
ELISA 1:5000-1:10000
IHC-P 1:100-1:500
Please Note: Optimal concentrations/dilutions should be determined by the end user.

Anti-PD-L1 Antibody (Rabbit Monoclonal 抗体) の画像

Immunochemical staining of human B7H1 in human placenta with rabbit monoclonal antibody (1:200, formalin-fixed paraffin embedded sections). Positive staining was localized to trophoblast.

Anti-PD-L1 Antibody: Alternative Names

Anti-B7-H Antibody; Anti-B7-H1 Antibody; Anti-B7H1 Antibody; Anti-PD-L1 Antibody; Anti-PDCD1L1 Antibody; Anti-PDCD1LG1 Antibody; Anti-PDL1 Antibody

PD-L1 Background Information

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.
Full Name
CD274 molecule
References
  • Iwai Y, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
  • Ghebeh H, et al. (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
  • Salih HR, et al. (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.
  • Wilcox RA, et al. (2009) B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 114(10): 2149-58.
  • Ruggiero A, et al. (2009) Crystal structure of PD-L1, a ribosome inactivating protein from Phytolacca dioica L. leaves with the property to induce DNA cleavage. Biopolymers. 91(12): 1135-42.
  • PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
    Author
    BJ Chen, B Chapuy, J Ouyang, HH Sun…
    Year
    2013
    Journal
    Clinical Cancer research
    Application
    binding
  • PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
    Author
    Soliman, H;Khalil, F;Antonia, S;
    Year
    2014
    Journal
    PLoS ONE
    Application
    IHC
  • Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
    Author
    Massari, F;Ciccarese, C;Caliò, A;Munari, E;Cima, L;Porcaro, AB;Novella, G;Artibani, W;Sava, T;Eccher, A;Ghimenton, C;Bertoldo, F;Scarpa, A;Sperandio, N;Porta, C;Bronte, V;Chilosi, M;Bogina, G;Zamboni, G;Tortora, G;Samaratunga, H;Martignoni, G;Brunelli, M;
    Year
    2015
    Journal
    Target Oncol
    Application
    IHC
  • PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
    Author
    Mahoney, KM;Sun, H;Liao, X;Hua, P;Callea, M;Greenfield, EA;Hodi, FS;Sharpe, AH;Signoretti, S;Rodig, SJ;Freeman, GJ;
    Year
    2015
    Journal
    Cancer Immunol Res
    Application
    IHC
  • Developing a LANCE TR-FRET Assay for Screening PD-1 and PD-L1 Binding Inhibitors
    Author
    Hinterneder, J;Hopkinton, MA;
    Year
    2017
    Journal
    Product
    Application
    control assay
  • Gene signature driving invasive mucinous adenocarcinoma of the lung
    Author
    Guo, M;Tomoshige, K;Meister, M;Muley, T;Fukazawa, T;Tsuchiya, T;Karns, R;Warth, A;Fink-Baldauf, IM;Nagayasu, T;Naomoto, Y;Xu, Y;Mall, MA;Maeda, Y;
    Year
    2017
    Journal
    EMBO Mol Med
    Application
    WB
カートに追加しました カートに追加しませんでした